Multicentre Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in African Children
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Cure rate
研究概览
简要总结
Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be actively investigated. The investigators will test the efficiency, safety and tolerance of combined fosmidomycin and clindamycin treatment in acute uncomplicated malaria in children aged 3-10 years.
详细描述
Few efficient drugs for malaria treatment are available so far. Due to increased exposure of these drugs and due to the high risk of development of drug resistant strains of Plasmodium falciparum, new drug combinations have to be actively investigated. The goal of this study is to assess a new drug combination, fosmidomycin-clindamycin. The primary objective of the study is to assess and compare the efficacy, safety and tolerance (between sites) of fosmidomycin and clindamycin when co-administered orally over three days in the treatment of acute uncomplicated Plasmodium falciparum malaria in children in Mozambique and Gabon.
The secondary objective is to differentiate between recrudescent parasitaemia and reinfection in the event of recurrent parasitaemia developing within the 28-day follow-up period, to determine the population pharmacokinetics of fosmidomycin when co-administered orally with clindamycin and to compare the in vitro sensitivity of isolates of Plasmodium falciparum to fosmidomycin.
The trial will include 100 children aged 3-10 years, divided between clinical sites of Gabon and Mozambique.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 10 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged three to ten years
- •Body weight ≥12kg
- •Acute (symptoms lasting less than 14 days) uncomplicated P falciparum malaria
- •Asexual parasitaemia between 1,000/µL and 200,000/µL
- •Ability to tolerate oral therapy
- •Willingness of the parent or guardian to provide informed signed consent
排除标准
- •Symptoms/signs of severe malaria, according to WHO criteria (see appendix I)
- •Body weight <12kg
- •Other concomitant plasmodial infections (P vivax, P ovale, P malariae)
- •Severe malnutrition with weight for height <70% (according to WHO tables) or clinical kwashiorkor
- •Gastro-intestinal disturbance with persistent vomiting (> three episodes within previous 24 hours) and/or diarrhoea (> 5 loose stools in the preceding 24 hours)
- •Concomitant disease masking assessment of response including sickle cell disease and severe cardiac, hepatic or renal impairment
- •Packed cell volume (PCV) on arrival <22%
- •Adequate anti-malarial treatment within previous 7 days
- •Inability to tolerate oral therapy
- •Parent or guardian deemed to be unsupportive
- •On co-trimoxazole prophylaxis
- •Any known allergies to the investigational products
研究组 & 干预措施
Fosmidomycin and clindamycin treatment
All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
干预措施: Fosmidomycin and clindamycin (Drug)
结局指标
主要结局
Cure rate
时间窗: Day 28
Cure rate at day 28 will be determined by PCR
次要结局
- cure rate(day 7)